2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2024

Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain – an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial
Abstract Number: 2025

Potential Clinical Utility of Manu-Scan, the Novel Optical Molecular Imaging, in Patients with Hand Rheumatoid Arthritis
Abstract Number: 2026

Pneumococcal Vaccination Rates: Improving Safety in Immunocompromised Patients
Abstract Number: 2027

Pre-Visit Planning Improves Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 2028

Compliance with Pneumococcal Vaccination in Rheumatic Disease Patients on Immunosuppressive Medications
Abstract Number: 2029

Improved Provider Awareness and Delivery of Zoster Vaccination in Patients with Rheumatoid Arthritis Contemplating Biologic Therapy: Need to Target Eligible Patients Prescribed for Vaccination Post-Clinic
Abstract Number: 2030

Patient Motivation in Inflammatory Arthritis: The Use of Ultrasound-Guided Patient Education to Endorse Medication Adherence and Facilitate Cost-Effective Targeted Management
Abstract Number: 2031

Online Viewing of Labs in RA Patients Is Not Associated with Clinically Significant Change in ESR over 18 Months Compared to Non-Viewers
Abstract Number: 2032

Evaluation of RA Outcome Measures between Users and Non-Users of the Patient Portal
Abstract Number: 2033

Low Health Literacy Does Not Impact Adherence to Hydroxychloroquine in Patients with Systemic Lupus
Abstract Number: 2034

New Guidelines on Hydroxychloroquine Dosage – Where Are We?
Abstract Number: 2035

Clinical Audit of Hydroxychloroquine Dosing and Toxicity Screening in Patients with Inflammatory Arthritis and Connective Tissue Diseases
Abstract Number: 2036

Rheumatologists’ Compliance with Screening for Viral Hepatitis B and C Prior to Initiation of Methotrexate Treatment Needs Quality Improvement
Abstract Number: 2037

HLA-B27 Testing in Patients >= 45 Years of Age and Subsequent Diagnosis of Late Onset Spondyloarthritis
Abstract Number: 2038

Radiological Changes Measured By MRI and High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Show Correlation with Michigan Hand Outcome Questionnaire (MHQ) in Rheumatoid Arthritis Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].